Can statins lessen the burden of virus mediated cancers?

Eva H. Clark1,2,6*, Sarah T. Ahmed2,3, Elaine Chang2,3, Elizabeth Y. Chiao4 and Donna L. White2,3,5

Abstract
Background: Oncogenic viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), Epstein Barr virus (EBV), and Kaposi Sarcoma Herpes virus (KSHV) contribute to a significant proportion of the world’s cancers. Given the sizeable burden of virus mediated cancers, development of strategies to prevent and/or treat these cancers is critical. While large population studies suggest that treatment with hydroxymethylglutaryl-CoA reductase inhibitors, commonly known as statins, may reduce the risk of many cancer types including HBV/HCV related hepatocellular carcinoma, few studies have specifically evaluated the impact of statin use in populations at risk for other types of virus mediated cancers.

Main body: Studies of populations with HBV and HCV suggest a protective, dose-dependent effect of statins on hepatocellular carcinoma risk and support the theory that statins may offer clinical benefit if used as chemoprophylactic agents to reduce liver cancer incidence. However, no population level data exists describing the impact of statins on populations with other oncogenic viral infections, such as HPV, EBV, and KSHV.

Conclusion: Further study of statin use in diverse, global populations with or at high risk for oncogenic viral infections is essential to determine the impact of statin therapy on virus mediated cancer risk.

Keywords: Oncogenic virus, Cancer, Statin, Virus-mediated malignancies, HBV, HCV, HPV, EBV, KSHV, HHV8
gaps for future investigation of the impact of statins on virus-mediated cancers.

Main text

Role of oncogenic virus infections on cancer development

While many viruses can cause chronic inflammation and immune dysregulation, only seven oncogenic viruses are known to cause human malignancies [4]. These seven diverse viruses share several characteristics that permit and facilitate carcinogenesis, including deactivation of tumor suppressor pathways, deregulation of host signaling pathways, blunting of the host response to DNA damage, and inhibition of antitumor immune surveillance and response [4–6]. However, while viral infection is necessary to cause certain cancers, it is not sufficient [5]. Additional factors, ranging from environmental exposures to host genetic and immunologic susceptibility, are likely necessary for malignant transformation of the host-cell genome [7]. Given the long latency period between viral infection and cancer development (often decades [7]), it may be possible to prevent or slow the development of virus mediated cancers by reducing an individual's exposure to any or all of the processes described above.

Impact of statins on cancer incidence and prognosis

As oncogenic virus infections are often asymptomatic and therefore can persist for years before detection, reduction or prevention of the disease caused by oncogenic virus infection via empiric treatment of at-risk populations with an oral medication that is safe and well-tolerated would be an ideal solution. Statins could represent such a medication. Statins were developed in the 1970s–80s to prevent arterial disease via reduction of total and low density lipoprotein (LDL) cholesterol levels [8]. Now they are widely prescribed for their therapeutic and primary and secondary preventive effects in cardiovascular disease [9–12].

The same characteristics that make statins attractive as a tool to prevent cardiovascular disease have led to interest in them as agents that may reduce cancer risk. Pre-clinical data suggest that statins have pleiotropic anti-inflammatory effects [13–19] and contribute to activation of molecular cascades essential to survival of cancer cells [20, 21]. Specifically regarding their potential to reduce cancers mediated by oncogenic viruses, some evidence suggests that statins inhibit HCV [22, 23] replication, downregulate HBV activity and replication [24], and improve the antiviral activity of several HCV therapies [25].

Numerous publications have evaluated the relationship between statins and various types of cancer [26, 27]. Though robust evidence for a positive relationship between statin use and reduced cancer risk has not been conclusively shown for all cancer types, several large, diverse, population-based epidemiologic studies note a lower cancer incidence and/or mortality in populations treated with statins, including for cancers such as colorectal [28–30], prostate [31–33], gastric [34], pancreatic [35, 36], liver [37–40], breast and cervical [41, 42], endometrial and ovarian [43, 44], and lymphoma [45, 46].

Statins and liver cancer caused by HBV and HCV

Statins have been considered specifically for liver cancer prevention as they undergo hepatic first-pass metabolism and sequester in the liver. Available data evaluating the question of whether statins directly reduce liver cancer incidence are limited by the fact that liver cancer is a rare cancer that takes years to develop and by the paucity of studies able to stratify their data by the various etiologies of liver cancer (e.g., viruses, aflatoxin exposure, alcohol exposure, and non-alcoholic fatty liver disease), as likely etiologies are regional and differ significantly among the populations studied to date. Even so, several meta-analyses show that statin use is significantly associated with a reduced risk of hepatocellular carcinoma (HCC) of any etiology [47, 48]. Specifically, statin use may lead to an improved virologic response to treatment and reduced risk of cirrhosis and HCC in populations with chronic HBV and HCV infections [49, 50]. Table 1 describes seven cohort studies evaluating the incidence of HCC in populations with chronic HBV or HCV infections. Despite significant heterogeneity in reporting methods, all seven studies found that the risk of incident HCC was significantly reduced in most types of statin user groups compared to non-users (Tables 2A [HBV] and Table 2B [HCV]). The hazard ratios describing HCC risk reported by the these studies are similar to effect ratios reported by previous systematic reviews and meta-analyses that evaluated statin use on risk of HCC of any cause (e.g., in [47], risk ratio = 0.60, 95% CI 0.53–0.69) and on risk of HCC in populations with HCV (e.g., in [49], relative risk = 0.45 [95% CI 0.36–0.57]).

Dose and duration of statin therapy appear to significantly impact risk of HCC, as shown in a 2016 meta-analysis of 25 studies (including 12 cohort studies, 10 case–control studies, and three post-hoc analyses of randomized controlled trials) providing the risk ratio (RR) for statin use and primary liver cancer (of any cause/ type) risk. This 2016 meta-analysis not only found that statin use was significantly associated with a reduced risk of primary liver cancer (RR = 0.60, 95% CI = 0.53–0.69), but also that the RR for every additional 50 cumulative defined daily doses per year was 0.87 (95% CI = 0.83–0.91) [47]. The same study suggested an additional benefit of statin use in high-risk populations, such as those with HBV or HCV infection; specifically, they estimated a RR...
Table 1  Characteristics of seven studies evaluating statins and incidence of liver cancer in people with hepatitis B or C virus infection

| Study   | Years of study | Country          | Study design                                      | Number of centers | Age (years) | No. total population initially evaluated | No. HBV included in analysis | No. HCV included in analysis | No. male | % male | Age (mean or median) | No. statin users | % statin user | Statins evaluated | Primary outcome |
|---------|----------------|------------------|--------------------------------------------------|-------------------|-------------|------------------------------------------|----------------------------|----------------------------|----------|--------|----------------------|-----------------|--------------|------------------|-----------------|
| Goh [52] | 2008–2012 South Korea | Retrospective cohort | Single center                                     | ≥ 18              | 12,950      | 7713                                     | N/A                        | 5106c                          | 66% c   | 50c   | 713                  | 9               | AF,P,Pi,R,S  | HCC incidence  |
| Hsiang [54] | 2000–2012 China | Retrospective landmark analysis, followed by propensity weighting | Nationwide cohort | ≥ 18              | 77,021      | 53,513                                  | N/A                        | 14,145c                          | 26% c   | 38c   | 1176                 | 2               | AF,R,S       | HCC incidence  |
| Simon [55] | 2001–2014 US | Retrospective cohort | Nationwide cohort | N/A              | 47,549      | N/A                                     | 9135                       | 8743c                          | 96% c   | 53    | 4165                 | 46              | AC,F,L,PS     | HCC incidence  |
| Simon [56]* | 2005–2013 Sweden | Prospective propensity score-matched cohort | Nationwide cohort | ≥ 18              | 16,668      | 3906                                     | 12,762                     | 1992c                          | 51% c   | 35c   | 1953 (HBV), 6381 (HCV) | 50              | AP,R,S       | HCC incidence  |
| Tsan [50] | 1997–2008 Taiwan | Retrospective cohort | Nationwide cohort | >18              | 33,413      | 33,413                                  | N/A                       | 19,442                          | 58%    | 36    | 2785                 | 8               | AF,L,PR,S    | HCC incidence  |
| Tsan [57] | 1999–2010 Taiwan | Retrospective cohort | Nationwide cohort | >18              | 260,864     | N/A                                     | 260,864                    | 128,263                         | 49%    | 50    | 35,023               | 13              | AF,L,PR,S    | HCC incidence  |
| Yang [58]** | 1996–2005 China | Retrospective cohort | Nationwide cohort | N/A              | 1319        | 204                                     | N/A                        | 141                             | 69%    | 52    | 148                  | 28              | Not specified | HCC incidence  |

*Note that this publication is included in both parts of Table 2 (its HBV data in Table 2A and its HCV data in Table 2B)

**This cohort includes only persons with diabetes

1 Value calculated from available study data

HBV hepatitis B virus, HCV hepatitis C virus, HCC hepatocellular carcinoma, US United States, A = atorvastatin, C cerivastatin, F fluvastatin, L lovastatin, P pravastatin, Pi pitavastatin, R rosuvastatin, S simvastatin
Table 2  (A) HCC Incidence and hazard ratios in studies evaluating people with HBV and (B) HCC incidence and hazard ratios in studies evaluating people with HCV

| Study | Follow up period | No. HCC cases | HCC incidence (%) | Model adjustment(s) | No. HCC cases | HCC incidence (%) | HCC incidence rate (per 100,000 py) | (a) HR and 95% CI | Statin users | Statin non-users |
|-------|------------------|---------------|-------------------|---------------------|---------------|-------------------|--------------------------------------|-----------------|-------------|----------------|
| Goh [52] | 7.2 years | 702         | 9.1              | N/A                 | 30            | 3.3               | N/A                                  | 0.36, 0.19–0.68 | 63, 0.31–1.29 | 0.51, 0.21–1.25 | 0.32, 0.07–0.68 | 0.35, 0.15–0.16 | 0.39, 0.15–1.05 | 672, 7.9        | Ref          |
| Hsiang [54] | 393,154 py | 1298        | 2.43              | Propensity score   | 36            | 3.1               | 1200                                 | 0.68, 0.36–0.97 | 2.8, 0.66–1.29 | 0.41, 0.27–0.67 | 0.34, 0.18–0.51 | 0.44, 0.33–0.59 | 0.51, 0.31–0.85 | 1262, 2.4       | Ref          |
| Simon [55] | 8 years | 136          | 3.5               | Propensity score   | 54            | 2.8               | 200F                                 | N/A             | 0.85, 0.48–1.53 | 0.94, 0.84–1.14 | 0.96, 0.87–1.10 | 0.92, 0.85–1.14 | 963, 3.1       | 320, Ref      |
| Tsan [50] | 328,946 py | 1021        | 3.1               | Age, sex, income, urbanization, diabetes, cirrhosis | 58            | 2.1               | 211                                  | 0.47, 0.36–0.61 | 0.66, 0.44–0.99 | 0.41, 0.27–0.61 | 0.34, 0.18–0.67 | 0.44, 0.33–0.59 | 0.51, 0.31–0.85 | 963, 3.1       | Ref          |
| Yang [58] | 578,22 py | 23           | 1.7               | Age, sex, tobacco, alcohol, BMI, cirrhosis | 1             | 2.9               | N/A                                  | 13.64, 0.84–221.23 | 0.54, 0.32–0.85 | 0.69, 0.47–1.47 | 0.54, 0.36–0.72 | 0.69, 0.47–1.47 | 57.22, 6.95–470.16 | 13, 8.9       | N/A          |

| Study | Follow up period | No. HCC cases | HCC incidence (%) | Model adjustment(s) | No. HCC cases | HCC incidence (%) | HCC incidence rate (per 100,000 py) | (a) HR and 95% CI | Statin users | Statin non-users |
|-------|------------------|---------------|-------------------|---------------------|---------------|-------------------|--------------------------------------|-----------------|-------------|----------------|
| Simon [55] | 9.7 mos (statin users); 8.1 mos (non-users) | 239            | 2.6              | Baseline FIB-4     | 73            | 1.8               | 200-280 [cDDD], 300-180 [cDDD], 100-180 [cDDD], 70-180 [cDDD], 50-180 [cDDD], 30-180 [cDDD], 20-180 [cDDD], 10-180 [cDDD] | 0.53, 0.36–0.72 | 0.85, 0.47–1.53 | 0.48, 0.27–0.88 | 0.51, 0.26–0.72 | 0.54, 0.36–0.83 | 0.56, 0.37–1.10 | 160, 3.2       | 465, Ref     |
| Simon [50] | 8 years | 480           | 3.8               | Propensity score   | 211           | 3.3               | 232F                                 | N/A             | 0.54, 0.45–0.67 | 0.56, 0.47–0.72 | 0.54, 0.45–0.67 | 0.56, 0.47–0.72 | 269, 4.2       | 377, Ref      |
### Table 2 (continued)

| Study | Follow up period | No. HCC cases | HCC incidence (%) | HCC incidence rate (per 100,000 py) |
|-------|------------------|---------------|-------------------|-------------------------------------|
| Tsan [57] | 2,792,017 py | 27,883 | 10.7 | 999 |
| | | | Age, sex, urbanization, income, cirrhosis, DM | 1378 | 3.9 | 341 |
| | | | Model adjustment(s) | (a) HR and 95% CI No. HCC cases HCC incidence (%) HCC incidence rate (per 100,000 py) |
| | | | | All 1st cDDD group 2nd cDDD group 3rd cDDD group 4th cDDD group LS group HS group |
| | | | | All 26,505 | 11.7 | 1110 | Ref |
| | | | | 0.53, 0.49-0.58 | 0.66, 0.59-0.74 | 0.47, 0.40-0.56 | 0.33, 0.25-0.42 | 0.66, 0.59-0.74 | 0.47, 0.40-0.56 | 0.33, 0.25-0.42 | 0.66, 0.59-0.74 | 0.47, 0.40-0.56 | 0.33, 0.25-0.42 |
| | | | | (28–89 cDDD) | (90–180 cDDD) | (> 180 cDDD) | (28–89 cDDD) | (90–180 cDDD) | (> 180 cDDD) |

(a) HR hazard ratio (adjusted HR reported if available), cDDD cumulative defined daily statin doses, DM diabetes, FIB-4 fibrosis-4 score, HBV hepatitis B virus, HCC hepatocellular carcinoma, HTN hypertension, HS hydrophilic statin users, LS lipophilic statin users, py person years, Ref reference

*Note that this publication is included in both tables (its HBV data in Table 2A and it’s HCV data in Table 2B)

**This cohort includes only persons with diabetes

† Value calculated from available study data
of 0.50 (95% CI = 0.36–0.69) for those with HBV infection and 0.53 (95% CI = 0.49–0.57) for those with HCV infection. In 2017, a large propensity-matched population study of patients with liver cirrhosis associated statin use with decreased risk of decompensation, mortality, and HCC in a dose-dependent manner, particularly in those with chronic HBV/HCV infections [51]. Collectively, this is suggestive supporting evidence that higher statin doses and/or longer statin durations of use may prevent or delay liver cancer development in people with chronic HBV/HCV infections.

Further, the question of whether lipophilic or hydrophilic statin use has a greater impact on HCC risk in HBV or HCV infected individuals has been specifically addressed by three studies. First, in Tsan et al’s 2012 large retrospective cohort study of people with HBV infections, both lipophilic and hydrophilic statin users had reduced risk of HCC development compared to statin non-users (adjusted HR was 0.44 [95% CI 0.33–0.59] for lipophilic statin users and 0.51 [0.31–0.85] for hydrophilic statin users) [50]. In contrast, Simon et al.’s 2019 prospective propensity-matched study found that 10-year HCC risk was significantly lower among lipophilic statin users compared to statin non-users but this risk reduction was not seen for hydrophilic statin users compared to statin non-users (for people with HBV, adjusted HR was 0.58 [95% CI 0.48–0.78] for lipophilic statin users and 0.94 [95% CI 0.84–1.14] for hydrophilic statin users; for people with HCV, adjusted HR was 0.54 [0.45–0.83] for lipophilic statin users and 0.96 [0.87–1.10] for hydrophilic statin users). Goh et al. reported similar findings in their 2020 single center study [52].

**Statins and cancers caused by HPV**

In contrast to HBV/HCV, few epidemiologic studies describe the impact of statin use on HPV-, EBV-, or KSHV-mediated cancers. For HPV, one retrospective cancer database study of 1638 individuals with head and neck cancers found a statistically significant inverse association between ever using a statin and death from HPV + head and neck cancers (HPV-positive HR = 0.41, 95% CI 0.21–0.84; HPV-negative HR = 1.04, 95% CI 0.71–1.51) [53].

**Conclusions and future directions**

Available data suggest a protective, dose-dependent effect of statins on HCC risk in populations with chronic HBV and/or HCV infections. Thus, statins may show clinical benefit if used as chemoprophylactic agents to reduce the public health burden of HCC, and randomized clinical trials evaluating the effectiveness of statins in HCC outcomes both with other therapies (NCT03275376) and to prevent recurrent HCC (NCT03024684) are ongoing. Trials being planned should include comparisons of lipophilic or hydrophilic statins in their designs.

The promise of statins in preventing HCC warrants extrapolation of epidemiologic and clinical study of statin therapy to populations at risk for other oncogenic viral infections, particularly HPV, EBV, and KSHV. Importantly, despite the much larger global burden of cervical cancer, the only published study describing the impact of statins on HPV is in HPV-related head and neck cancers, which are predominantly diagnosed in men in high income countries. Future studies must rectify this disparity by evaluating the impact of statins on cervical cancer, particularly in low- and middle-income countries where cervical cancer rates are higher due to poor access to HPV vaccines and surveillance programs, but also in high income countries where cervical cancer remains an important cause of cancer morbidity and mortality despite robust HPV prevention programs. Statin therapy might prevent or slow the development of cervical cancer if initiated immediately after detection of high-risk HPV subtypes or cervical dysplasia in women undergoing cervical cancer screening. Though pre-clinical data suggest that statin therapy may ameliorate EBV-related cancers, no epidemiologic studies have evaluated statins in prevention or as an adjunctive therapy in at risk populations. Such studies are needed to determine whether statin intervention trials are warranted to prevent EBV-related cancers. Though KSHV afflicts a large proportion of the population, particularly in sub-Saharan Africa, no investigations into the ability of statin therapy to limit the development of KSHV-associated cancers exist; study of the relationship between KSHV and statins should be initiated via in vitro and animal model studies. Finally, HIV hugely impacts risk of morbidity and mortality in those co-infected with the oncogenic viruses covered in this Review, and several anti-retroviral therapies in widespread use are known to contribute to dyslipidemia. Future research should include investigation of statins as agents to prevent virus mediated cancers in people with HIV, as these individuals may have different outcomes or require different statin doses.

The studies outlined in this article provide preliminary evidence that statins may induce mechanisms that slow virus-mediated cancer development, which should be further investigated in epidemiologic studies of populations at risk for HPV, EBV, and KSHV infection. Randomized trials and large community-based prevention trials prospectively evaluating use of specific statins in populations with or at high risk for oncogenic viral infections will be needed to further explore the potential benefit of statins in decreasing virus mediated cancer risk.
Abbreviations
EBV: Epstein-Barr virus; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HPV: Human papilloma viruses; KSHV: Kaposi Sarcoma Herpes virus; LDL: Low density lipoprotein; NPC: Nasopharyngeal carcinoma.

Author contributions
EHC drafted the final form of this manuscript. All authors read and approved the final manuscript.

Funding
Funding support: (1) VA Health Services Research & Development Center of Innovation grant CIN 13-413 (EHC received salary support in part from the Houston VA HS&R Center for Innovations in Quality, Effectiveness and Safety [CIN13-413] Advanced Fellowships Program in Health Services Research), (2) EYC and JRK receive funding from NIH grant 1R03 CA206476, (3) EC received funding from NIH grant T32 CA174647, (4) EYC receives funding from AIDS Malignancy Consortium grant 2U01CA121947-04 and P30 CA25123 (Dan L. Duncan Comprehensive Cancer Center), (5) DW receives salary support from the U.S. Department of Veterans Affairs Clinical Science Research and Development program (CX001430), and (6) EHC received salary support in part from NIH grant 1K23AI68583-01.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
This manuscript is not a study involving human participants or animals, thus ethics approval and consent to participate were not required.

Consent for publication
This manuscript does not contain any individual person’s data in any form.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2 Center for Innovation, Quality, Effectiveness and Safety (IQcEST), Michael E. DeBakey VA Medical Center, Houston, TX, USA. 3 Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 4 Departments of Epidemiology and General Oncology, MD Anderson Cancer Center, Houston, TX, USA. 5 Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA. 6 Section of Pediatric Tropical Medicine, Baylor College of Medicine, Feigin Building Suite 550, Houston, TX 77030, USA.

Received: 9 January 2022 Accepted: 22 August 2022
Published online: 04 September 2022

References
1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90.
2. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16.
3. Park-LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012. AIDS. 2016;30(11):1795–806.
4. Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. Nat Rev Microbiol. 2018;16(11):684–98.
5. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;13(3):265–82.
6. Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59–73.
7. Zur HH. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1–10.
8. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569–82.
9. Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014;45(10):2974–82.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.
11. Briel M, Vale N, Schwartz-GG, de Lemos JA, Colivicchi F, den Hartog FR, et al. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012;158(1):93–100.
12. Kjekshus J, Apetrei E, Barrios V, Bohn M, Cleland JG, Cornell JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–61.
13. Yeganeh B, Wiechece E, Ande SR, Sharma P, Moghadam AR, Post M, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87–110.
14. Wong WW, Dimitrakou J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508–19.
15. Pich C, Teiti I, Rochax P, Mariame B, Couduc B, Favre G, et al. Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol. 2013;4:652.
16. Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):10–7.
17. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender R, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2008;197(2):829–39.
18. Jalal I, Stein D, Balis D, Grundy SM, Adams-Huetl B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103(15):1933–5.
19. Chan KK, Ozma AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10–9.
20. Gronicz N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10(11):625–42.
21. Spampinato C, De Maria S, Sarnataro M, Giordano E, Zanardin M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935–41.
22. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA. 2003;100(26):15865–70.
23. Delang L, Paehuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology. 2009;50(1):6–16.
24. Li W, Cao F, Li J, Wang Z, Ren Y, Liang Z, et al. Simvastatin exerts anti-hepatitis B virus activity by inhibiting expression of minichromosome maintenance protein 7 in HepG2.2.15 cells. Mol Med Rep. 2016;14(6):5334–42.
25. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864–74.
26. Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, et al. Statin and cancer mortality and survival: an umbrella systematic review and meta-analysis. J Clin Med. 2020;9(2):256.
27. Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, et al. Effect of statin on cancer incidence: an umbrella systematic review and meta-analysis. J Clin Med. 2019;8(6):819.
28. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2006;355(21):2189–92.
29. Han KT, Kim S. Do cholesterol levels and continuity of statin use affect colorectal cancer incidence in older adults under 75 years of age? PLoS ONE. 2021;16(4):e0250716.
30. Li Y, He X, Ding Y, Chen H, Sun L. Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta-analysis. Cancer Med. 2019;8(6):3305–13.

31. Farwell WR, D’Avolio LW, Scantlon RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885–92.

32. Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2020;26(5):1086–93.

33. Van Rompay MJ, Solomon KR, Nickel JC, Ranganathan G, Kantoff PW, McKinlay JB. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118–26.

34. Seo SI, Park CH, Kim TJ, Bang CS, Kim JY, Lee KJ, et al. Aspirin, metformin, and statin use on the risk of gastric cancer: a nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer Med. 2022;11(16):1217–31.

35. E JY, Lu SE, Lin Y, Graber JM, Rotter D, Zhang L, et al. Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1225–32.

36. Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas. 2019;48(2):142–50.

37. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38(5):523–7.

38. Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106(5):894–8.

39. McGlynn KA, Haagberg K, Chen J, Graubard BI, London WT, Jick S, et al. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst. 2015;107(4):djv009.

40. Tran KT, McMenamin UC, Coleman HG, Cardwell CR, Murchie P, Iversen L, et al. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer. 2020;146(1):1250–60.

41. McMenamin UC, Murray LJ, Hughes CM, Cardwell CR. Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer. 2016;16:600.

42. Kim DS, Ahn HS, Kim HJ. Statin use and incidence and mortality of breast and gynecology cancer: a cohort study using the National Health Insurance claims database. Int J Cancer. 2022;150(1):1156–65.

43. Couttenier A, Lacroix O, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study. PLoS ONE. 2017;12(12):e0189233.

44. Chen Y, Han L, Zheng A. Association between statin use and the risk of gynecologic cancer: a meta-analysis. J Eur Obstet Gynecol Reprod Biol. 2022;268:74–81.

45. Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, et al. Statin use and risk of lymphoid neoplasms: results from the European Case–Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev. 2006;15(5):921–5.

46. Ye X, Minea A, Johnston JB, Mahmud SM. Associations between statin use and non-Hodgkin lymphoma (NHL) risk and survival: a meta-analysis. Hematol Oncol. 2017;35(2):206–14.

47. Zhong CC, Liu Y, Ye YY, Hao FB, Wang K, Gong JP. Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep. 2016;6:26256.

48. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32.

49. Zheng YY, Zhou PC, Zhou RR, Fan XG. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(7):759–66.

50. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623–30.

51. Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decomposition in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907.